About
Kris Barnes, PhD is the founder and CEO of Lento Bio, a New York-based preclinical therapeutics company developing small-molecule eyedrops for presbyopia and other age-related conditions. He earned a BS in Biology from SUNY Oswego and a PhD in Neuroscience from Weill Cornell Medicine, then worked as a biotech/pharma consultant before founding Lento Bio in 2022. Public sources position him as a longevity-focused biotech operator working at the intersection of aging biology and ophthalmology.
Areas of interest
longevitybiotechophthalmologyage-related diseasesmall-molecule therapeuticspresbyopiadrug development